SAVE 10% ON MEMBRANE, SARS-CoV-2 AND ADC PRODUCTS!
Tweet, Share, View all associated products with this promotion!
Sep 1 2021
Nov 1 2021
View a complete listing of all associated products with this promotion. Still need more help? Please contact customer service to relieve any additional questions you may have.
Save 10% on Popular Proteins from AcroBiosystems
As we are suffering the epidemic caused by the ever-changing variants, we are facing the “Red Queen” racing between SARS-CoV-2 evolution and human defenses. Whether current therapeutic antibodies and vaccines against the circulating and emerging variants can provide enough protection becomes a primary concern.
ACROBiosystems are going full steam ahead on developing a collection of recombinant antigens for emergency SARS-CoV-2 variants, including the newly VOI, Lambda. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
Antibody-drug conjugates are highly targeted therapies that use biopharmaceutical drugs comprising monoclonal antibodies to target tumor cell specific antigens and extremely potent anti-cancer drugs linked through chemical linker. ADCs are considered a powerful and highly effective class of therapeutic agents used in oncology and hematology. The global Antibody-Drug Conjugates (ADCs) market size is expected to reach USD 20.01 Billion according to latest analysis.
In order to accelerate the development of ADC drugs, ACROBiosystems has developed a series of products with different species and tags for a variety of ADCs targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. The high purity and affinity were verified by MALS and SPR/BLI/cell based respectively, and protocols are available for free.
Targets for CAR-T cell therapy
Evaluating CAR expression is an essential step in the production of CAR-T cells. This is often done by flow cytometry, using protein L, anti-Fab antibodies, anti-idiotypic antibody or target antigens as detection antibodies. Among these common choices, target antigens are widely considered to be the best option, because it offers high specificity and minimal background staining.
ACROBiosystems has successfully developed an extensive collection of recombinant proteins, such as BCMA, CD19, CD22 and DLL3 for CAR-T therapy development. This growing list of proteins includes many fluorescent-labeled antigens , biotinylated proteins and unconjugated proteins that are uniquely suitable for evaluation of CAR expression.
- 50+CAR T targets, and PE, FITC, Biotin-labeled proteins are available
- FDA DMF filed products are available
- High specificity and sensitivity verified by FACS and protocol offered.
- Ideal for detecting CAR expression
Multi-pass Transmembrane Proteins
Many human diseases are associated with abnormal functions of these multi-pass transmembrane proteins and their role in variety of signaling pathways makes them ideal drug targets. However, multi-pass transmembrane proteins are very difficult to purify due to complex structures with multiple hydrophobic transmembrane regions and low expression level in host cells. Full length multi-pass transmembrane proteins with native conformation are needed to fully characterize antibody activity and mechanism of action.
With advantage platforms, ACROBiosystems provides full-length multi-pass transmembrane proteins including:
- Claudin 18.2
Click here to view a complete list of applicable products and start saving!
Have questions? Need more information? Contact us at firstname.lastname@example.org to have all your questions answered in a timely and professional manner.
Note: This offer is not valid in conjunction with contract discounts or any other special pricing. Void where prohibited.